Abstract

Case Report

Pulmonary Pleomorphic Carcinoma: A Rare Entity Revisited!

Deshmukh Mahesh K, Galani Komal S*, Mishra Manisha and Ingale Pooja

Published: 04 June, 2025 | Volume 9 - Issue 1 | Pages: 023-025

Introduction: Pleomorphic Carcinoma (PC) is a subset of poorly differentiated non–small cell lung cancer that is diagnostically challenging because it is a rare malignancy of the lung. It shows varying dual-cell components; spindle or giant cells and epithelial cells.
Method: We report a case of 68-year-old non-smoking female who presented with cough, fever, pain in the left side of chest & weight loss of recent onset and an abnormal shadow on her chest X-ray. Computed tomography of chest revealed a well defined heterogeneously enhancing cavitatory soft tissue lesion in the posterior basal segment of the left lower lobe with mediastinal lymphadenopathy.
Results: Fine needle aspiration cytology& percutaneous lung biopsy confirmed poorly differentiated malignant tumor. Patient underwent a left lower lobectomy. A diagnosis of PC was confirmed after Immunohistochemistry (IHC). Mutation analysis revealed an EGFR exon 21 mutation within the tumor cells. The patient is on Gefitinib based chemotherapy and has remained disease-free for three years post-surgery.
Conclusion: PC of the lung is a rare pathological entity. Definite diagnosis may only be made on a resected tumor along with the use of IHC. Surgical resection is the main modality of the treatment. Such rare cases should be documented to establish an optimal management plan and to provide a further insight to targeted therapy.

Read Full Article HTML DOI: 10.29328/journal.jprr.1001069 Cite this Article Read Full Article PDF

Keywords:

EGFR; Pulomonary pleomorphic carcinoma; Surgical resection

References

  1. Chang YL, Lee YC, Shih JY, Wu CT. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer 2001; 34: 91–97. Available from: https://doi.org/10.1111/j.1348-0421.2008.00083.x
  2. Kerr KM, Pelosi G, Austin JHM. World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2017:88–90.
  3. Rossi G, Cavazza A, Sturm N, Migaldi M, Facciolongo N, Longo L, Maiorana A, Brambilla E. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol. 2003;27(3):311-24. Available from: https://doi.org/10.1097/00000478-200303000-00004
  4. Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol. 2010;5(4):460-5. Available from: https://doi.org/10.1097/jto.0b013e3181ce3e3c
  5. Zhang X, Wang Y, Zhao L, Jing H, Sang S, Du J. Pulmonary pleomorphic carcinoma: A case report and review of the literature. Medicine (Baltimore). 2017;96(29):e7465. Available from: https://doi.org/10.1097/md.0000000000007465
  6. Kawamura A, Tanaka Y, Inoue Y, Tsuchida T, Katsumata M, Karayama M, et al. EGFR-mutated, metastatic pulmonary pleomorphic carcinoma successfully treated with afatinib, Current Problems in Cancer: Case Reports. 2022:6:100160. Available from: https://doi.org/10.1016/j.cpccr.2022.100160
  7. Jia X, Chen G. EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features. Contemp Oncol (Pozn). 2015;19(1):22-7. Available from: https://doi.org/10.5114/wo.2014.43491

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

  • Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC
    Tobias R Overbeck*, Stefan HP Wenleder*, Bernhard C Danner, Wolfgang Körber, Karin Toepelt, Bernhard Hemmerlein, Christina Perske, Markus Falk, Markus Tiemann, Claudia Tomala, Elke Stitz and Frank Griesinger Tobias R Overbeck*,Stefan HP Wenleder*,Bernhard C Danner,Wolfgang Körber, Karin Toepelt,Bernhard Hemmerlein, Christina Perske,Markus Falk,Markus Tiemann,Claudia Tomala,Elke Stitz,Frank Griesinger. Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC. . 2021 doi: 10.29328/journal.jprr.1001018; 5: 001-018
  • Pulmonary congenital cystic adenomatoid malformation: a rare congenital abnormality in adults and review of literature
    Iftikhar Ahmed Chaudhry*, Mohammad Nasim Khan, Yousif A Alqahtani, Abdullah Alghamdi, Othman M AlFraih, Meenal A AlAbdulhai and Ikram Ul-Haq Chaudhry Iftikhar Ahmed Chaudhry*,Mohammad Nasim Khan,Yousif A Alqahtani,Abdullah Alghamdi,Othman M AlFraih,Meenal A AlAbdulhai,Ikram Ul-Haq Chaudhry. Pulmonary congenital cystic adenomatoid malformation: a rare congenital abnormality in adults and review of literature. . 2022 doi: 10.29328/journal.jprr.1001038; 6: 016-019
  • Pulmonary Pleomorphic Carcinoma: A Rare Entity Revisited!
    Deshmukh Mahesh K, Galani Komal S*, Mishra Manisha and Ingale Pooja Deshmukh Mahesh K,Galani Komal S*,Mishra Manisha,Ingale Pooja. Pulmonary Pleomorphic Carcinoma: A Rare Entity Revisited!. . 2025 doi: 10.29328/journal.jprr.1001069; 9: 023-025

Recently Viewed

Read More

Most Viewed

Read More

Help ?